Financial Counselors Inc. Has $3.89 Million Stock Position in West Pharmaceutical Services, Inc. (NYSE:WST)

Financial Counselors Inc. lifted its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 3.3% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,815 shares of the medical instruments supplier’s stock after purchasing an additional 374 shares during the quarter. Financial Counselors Inc.’s holdings in West Pharmaceutical Services were worth $3,892,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Fidelis Capital Partners LLC acquired a new position in shares of West Pharmaceutical Services during the first quarter valued at about $27,000. Crewe Advisors LLC raised its stake in shares of West Pharmaceutical Services by 322.7% in the second quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 71 shares during the last quarter. Quarry LP boosted its position in shares of West Pharmaceutical Services by 155.3% during the fourth quarter. Quarry LP now owns 97 shares of the medical instruments supplier’s stock valued at $34,000 after buying an additional 59 shares during the last quarter. Hazlett Burt & Watson Inc. bought a new stake in West Pharmaceutical Services during the first quarter worth $40,000. Finally, Northwest Investment Counselors LLC purchased a new stake in West Pharmaceutical Services in the 1st quarter valued at $40,000. 93.90% of the stock is currently owned by institutional investors.

West Pharmaceutical Services Price Performance

WST opened at $313.63 on Tuesday. West Pharmaceutical Services, Inc. has a 1 year low of $265.00 and a 1 year high of $415.73. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.34 and a quick ratio of 1.68. The company has a market capitalization of $22.75 billion, a price-to-earnings ratio of 41.38, a P/E/G ratio of 11.15 and a beta of 1.01. The firm’s fifty day moving average price is $309.34 and its two-hundred day moving average price is $342.71.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). The firm had revenue of $702.10 million during the quarter, compared to the consensus estimate of $729.36 million. West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. The company’s revenue for the quarter was down 6.9% on a year-over-year basis. During the same period in the previous year, the company posted $2.11 earnings per share. As a group, analysts anticipate that West Pharmaceutical Services, Inc. will post 6.44 earnings per share for the current fiscal year.

Insider Activity at West Pharmaceutical Services

In other West Pharmaceutical Services news, VP Charles Witherspoon sold 1,029 shares of the company’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $300.00, for a total value of $308,700.00. Following the completion of the transaction, the vice president now owns 1,478 shares in the company, valued at approximately $443,400. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, SVP Silji Abraham sold 1,800 shares of the stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $330.78, for a total transaction of $595,404.00. Following the sale, the senior vice president now owns 2,860 shares of the company’s stock, valued at approximately $946,030.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Charles Witherspoon sold 1,029 shares of West Pharmaceutical Services stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $300.00, for a total value of $308,700.00. Following the transaction, the vice president now directly owns 1,478 shares of the company’s stock, valued at approximately $443,400. The disclosure for this sale can be found here. 0.53% of the stock is currently owned by company insiders.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.